Restaging transurethral resection of bladder tumor for high-risk stage Ta and T1 bladder cancer

Current Urology Reports

Volumn 13, Issue 2, 2012, Pages 109-114

  Ramírez Backhaus, Miguel ^a   Domínguez Escrig, José ^a   Collado, Argimiro ^a   Rubio Briones, José ^a   Solsona, Eduardo ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Bladder cancer; Bladder tumor; High risk superficial bladder cancer; Non muscle invasive bladder cancer; Transurethral resection

Indexed keywords

BCG VACCINE;

BLADDER CANCER; BLADDER PAPILLOMA; BLADDER SURGERY; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER STAGING; CARCINOMA IN SITU; CYSTECTOMY; DETRUSOR MUSCLE; HUMAN; PHOTODYNAMIC DIAGNOSIS; PROGNOSIS; REVIEW; SURGICAL TRAINING; TRANSURETHRAL RESECTION OF BLADDER TUMOR; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VOLUME;

CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; FEMALE; HUMANS; MALE; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURGICAL PROCEDURES, MINIMALLY INVASIVE; TREATMENT OUTCOME; URETHRA; URINARY BLADDER NEOPLASMS;

EID: 84860715265     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-012-0234-4     Document Type: Review

References (32)

1. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27:289.
2. •• Babjuk M, Oosterlinck W, Sylvester R et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 59:997. The European agreement in the management of pT1G3 has been updated this edition. Now, European guidelines recommend re-TUR of T1 high-risk bladder cancer.
3. Brausi M, Collette L, Kurth K, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002;41:523.
4. •• Divrik RT, Sahin AF, Yildirim U et al. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol. 58:185. This study showed that second TUR decreased the recurrence and progression rates in patients with newly diagnosed T1 disease compared to patients with T1 disease but with no second TUR.
5. El-Abbady AA, Shoukry MS, Hanno AG, et al. Repeated transurethral resection of recurrent superficial bladder tumors-does it affect the spread and stage of the tumor? Scand J Urol Nephrol. 2002;36:60.
6. Dotan ZA, Kavanagh K, Yossepowitch O, et al. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival. J Urol. 2007;178:2308.
7. •• Herr HW, Donat SM. Quality control in transurethral resection of bladder tumors. BJU Int. 2008;102:1242. Dr. Herr and colleagues from MSKCC lead this current of opinion.
8. Mariappan P, Smith G, Lamb AD, et al. Pattern of recurrence changes in noninvasive bladder tumors observed during 2 decades. J Urol. 2007;177:867.
9. •• Mariappan P, Zachou A, Grigor KM. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol. 57:843. The authors observed that the recurrence rate when detrusor muscle was absent and present were 44.4% and 21.7%, respectively (OR 2.9; 95% CI: 1.6-5.4; P 0 0.0002).
10. Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol. 1999;162:74.
11. Dutta SC, Smith Jr JA, Shappell SB, et al. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol. 2001;166:490.
12. Mersdorf A, Brauers A, Wolff J. Second TUR for superficial bladder cancer: A must? The journal of urology. 1998;159:143.
13. Vasdev N, Vasdev N, McKiea C, Dominguez-Escrig J, et al. The role of early re-resection in pTaG3 transitional cell carcinoma of the urinary bladder. British Journal of Medical and Surgical Urology. 2011;4:158-65.
14. Schips L, Augustin H, Zigeuner RE, et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology. 2002;59:220.
15. Han KS, Joung JY, Cho KS, et al. Results of repeated transurethral resection for a second opinion in patients referred for nonmuscle invasive bladder cancer: the referral cancer center experience and review of the literature. J Endourol. 2008;22:2699.
16. Dalbagni G, Kaag M, Cronin A et al. Variability of treatment selection among surgeons for patients with cT1 urothelial carcinoma. BJU Int. 106:1502
17. Zurkirchen MA, Sulser T, Gaspert A, et al. Second transurethral resection of superficial transitional cell carcinoma of the bladder: a must even for experienced urologists. Urol Int. 2004;72:99.
18. Ali MH, Ismail IY, Eltobgy A, et al. Evaluation of second-look transurethral resection in restaging of patients with nonmuscleinvasive bladder cancer. J Endourol. 2010;24:2047.
19. Geavlete P, Jora T, Georgescu D et al. Value of a second tur in bladder tumors evaluation and treatment. Eur Urol. 2002;Supplements, 120
20. •• Vianello A, Costantini E, Del Zingaro M, et al. Repeated White Light Transurethral Resection of the Bladder in Nonmuscle- Invasive Urothelial Bladder Cancers: Systematic Review and Meta-Analysis. J Endourol. 2011;25:11. This is the only systematic review in this issue. The study documented high percentages of persistence and upstaging bladder tumor after a TUR.
21. Herr HW. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette- Guerin therapy. J Urol. 2005;174:2134.
22. Herr HW, Donat SM, Dalbagni G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol. 2007;177:75.
23. Jocham D, Stepp H, Waidelich R. Photodynamic diagnosis in urology: state-of-the-art. Eur Urol. 2008;53:1138.
24. Cauberg EC, de Bruin DM, Faber DJ, et al. A new generation of optical diagnostics for bladder cancer: technology, diagnostic accuracy, and future applications. Eur Urol. 2009;56:287.
25. Cauberg EC, de la Rosette JJ, de Reijke TM. How to improve the effectiveness of transurethral resection in nonmuscle invasive bladder cancer? Curr Opin Urol. 2009;19:504.
26. Hungerhuber E, Stepp H, Kriegmair M, et al. Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology. 2007;69:260.
27. Fradet Y, Grossman HB, Gomella L, et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007;178:68.
28. Grimm MO, Steinhoff C, Simon X, et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol. 2003;170:433.
29. Herr HW, Donat SM. A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int. 2006;97:1194.
30. Schwaibold HE, Sivalingam S, May F, et al. The value of a second transurethral resection for T1 bladder cancer. BJU Int. 2006;97:1199.
31. Brauers A, Buettner R, Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? J Urol. 2001;165:808.
32. Dalbagni G, Herr HW, Reuter VE. Impact of a second transurethral resection on the staging of T1 bladder cancer. Urology. 2002;60:822.